Search for a networks
APL-A-005-02: Phase I - II clinical and pharmacokinetic study of Aplidin (APL) as a 3-hour intravenous infusion every 2 weeks, in children with refractory or relapsed malignant tumours and leukemia (coordination)
- Type of network : Multinational clinical trials
- Geographic coverage : European
- Funding body(ies) : -
- Sponsor : Pharma mar sa
Last update: March 2011
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.